A Study of UK-369,003 on the Safety and Efficacy in Patients With COPD

Back to Search
Print
Bookmark Trial

NCT00163098

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Ciudad de Cordoba, Cordoba, CP 5016, Argentina
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Chronic Obstructive Pulmonary Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
35-75 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- GOLD criteria 2 to 4

- 10 pack year history of smoking

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Women of child bearing potential

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Chronic Obstructive Pulmonary DiseaseEffects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease
NCT01072396
  1. Birmingham, Alabama
  2. Jasper, Alabama
  3. Torrance, California
  4. Hartford, Connecticut
  5. Springfield, Illinois
  6. Muncie, Indiana
  7. Livonia, Michigan
  8. Lebanon, New Hampshire
  9. Charlotte, North Carolina
  10. Pittsburgh, Pennsylvania
  11. Spartanburg, South Carolina
  12. Kingston, Ontario
  13. Montreal, Quebec
  14. Montreal, Quebec
  15. Ste-Foy, Quebec
ALL GENDERS
40 Years+
years
MULTIPLE SITES
Chronic Obstructive Pulmonary DiseaseCOPE With COPD Trial
NCT02343055
  1. Amherstburg, Ontario
  2. Chatham, Ontario
  3. Harrow, Ontario
  4. Leamington, Ontario
ALL GENDERS
40 Years+
years
MULTIPLE SITES
Chronic Obstructive Pulmonary DiseaseAssessment of Health-status of Patients With Chronic Obstructive Pulmonary Disease (COPD) on Maintenance Therapy With Spiriva HH Measured by COPD Assessment Test (CAT) Test
NCT01644734
  1. Andrychow,
  2. Bialystok,
  3. Bialystok,
  4. Bialystok,
  5. Bialystok,
  6. Bialystok,
  7. Bielsko-Biala,
  8. Bielsko-Biala,
  9. Bielsko-Biala,
  10. Biskupiec,
  11. Bochnia,
  12. Brzesko,
  13. Brzesko,
  14. Brzeziny,
  15. Brzozow,
  16. Bydgoszcz,
  17. Bydgoszcz,
  18. Bydgoszcz,
  19. Bydgoszcz,
  20. Bydgoszcz,
  21. Chelmsko Slaskie,
  22. Chelm,
  23. Chelm,
  24. Chodziez,
  25. Chojnice,
  26. Chorzow,
  27. Chorzow,
  28. Ciechanow,
  29. Czarnkow,
  30. Czestochowa,
  31. Czestochowa,
  32. Dabrowa Gornicza,
  33. Domaradz,
  34. Dziergowice,
  35. Gdansk,
  36. Gdansk,
  37. Gdansk,
  38. Gdansk,
  39. Gdansk,
  40. Gdansk,
  41. Gdansk,
  42. Gdansk,
  43. Gdynia,
  44. Gliwice,
  45. Glucholazy,
  46. Gora,
  47. Gorzow Wielkopolski,
  48. Grodzisk Mazowiecki,
  49. Grodzisk Mazowiecki,
  50. Gryfice,
  51. Jaroslaw,
  52. Jaslo,
  53. Jaslo,
  54. Jaslo,
  55. Jedrzejow,
  56. Jelenia Gora,
  57. Katowice,
  58. Katowice,
  59. Katowice,
  60. Katowice,
  61. Kcynia,
  62. Kielce,
  63. Kielce,
  64. Kielce,
  65. Klodzko,
  66. Kolobrzeg,
  67. Konin,
  68. Konskie,
  69. Konskie,
  70. Koszalin,
  71. Koszalin,
  72. Krakow,
  73. Krakow,
  74. Krakow,
  75. Krakow,
  76. Krakow,
  77. Krakow,
  78. Krakow,
  79. Krakow,
  80. Krakow,
  81. Krasnik,
  82. Krasnik,
  83. Krasnik,
  84. Krosno,
  85. Kutno,
  86. Ledziny,
  87. Legionowo,
  88. Lisnik Duzy,
  89. Lodz,
  90. Lodz,
  91. Lodz,
  92. Lodz,
  93. Lodz,
  94. Lomza,
  95. Lomza,
  96. Lowicz,
  97. Luban,
  98. Lubartow,
  99. Lubin,
  100. Lubin,
  101. Lubin,
  102. Lubliniec,
  103. Lublin,
  104. Lublin,
  105. Lublin,
  106. Lublin,
  107. Lubon,
  108. Ludwikowo,
  109. Lukow,
  110. Makow Mazowiecki,
  111. Malbork,
  112. Mielec,
  113. Milicz,
  114. Myslowice,
  115. Myszkow,
  116. Nisko,
  117. Nowy Dwor Gdanski,
  118. Nowy Sacz,
  119. Olawa,
  120. Olecko,
  121. Olsztyn,
  122. Opatow,
  123. Ostrowiec Swietokrzyski,
  124. Ostrowiec Swietokrzyski,
  125. Pabianice,
  126. Papowo Biskupie,
  127. Pawonkow,
  128. Piekary Slaskie,
  129. Pietrzykowice,
  130. Pila,
  131. Piotrkow Trybunalski,
  132. Plock,
  133. Pniewy,
  134. Poniatowa,
  135. Poznan,
  136. Poznan,
  137. Poznan,
  138. Poznan,
  139. Poznan,
  140. Prabuty,
  141. Proszowice,
  142. Pruszcz Gdanski,
  143. Przemysl,
  144. Rabka Zdroj,
  145. Radom,
  146. Radom,
  147. Ruda Slaska,
  148. Ruda Slaska,
  149. Ruda Slaska,
  150. Ruda Slaska,
  151. Rumia,
  152. Rumia,
  153. Rumia,
  154. Rybnik,
  155. Rybnik,
  156. Rybnik,
  157. Rzeszow,
  158. Rzeszow,
  159. Sanok,
  160. Sawin,
  161. Sejny,
  162. Siewierz,
  163. Skarzysko Kamienna,
  164. Skawina,
  165. Skoczow,
  166. Skrzyszow,
  167. Slawno,
  168. Slubice,
  169. Slupca,
  170. Sokolowsko,
  171. Sopot,
  172. Sosnowiec,
  173. Sosnowiec,
  174. Srem,
  175. Srem,
  176. Stalowa Wola,
  177. Starachowice,
  178. Starachowice,
  179. Stargard Szczecinski,
  180. Sucha Beskidzka,
  181. Suprasl,
  182. Suwalki,
  183. Suwalki,
  184. Swidnik,
  185. Swiecie,
  186. Sycow,
  187. Szczecinek,
  188. Szczecin,
  189. Szczecin,
  190. Szczecin,
  191. Szczecin,
  192. Szczecin,
  193. Tarnobrzeg,
  194. Tarnobrzeg,
  195. Tarnowskie Gory,
  196. Tarnow,
  197. Tarnow,
  198. Torun,
  199. Torun,
  200. Torun,
  201. Trzcianka Lubuska,
  202. Twardogora,
  203. Tychy,
  204. Tychy,
  205. Uchanie,
  206. Walcz,
  207. Warszawa,
  208. Warszawa,
  209. Warszawa,
  210. Warszawa,
  211. Warszawa,
  212. Warszawa,
  213. Warszawa,
  214. Warszawa,
  215. Warszawa,
  216. Warszawa,
  217. Warszawa,
  218. Warszawa,
  219. Warszawa,
  220. Warszawa,
  221. Warszawa,
  222. Wejherowo,
  223. Wieliczna,
  224. Wielun,
  225. Witonia,
  226. Wloc³awek,
  227. Wodzislaw Slaski,
  228. Wolomin,
  229. Wroclaw,
  230. Wroclaw,
  231. Wroclaw,
  232. Wroclaw,
  233. Wroclaw,
  234. Wroclaw,
  235. Wroclaw,
  236. Zabkowice Slaskie,
  237. Zabkowice Slaskie,
  238. Zabrze,
  239. Zabrze,
  240. Zabrze,
  241. Zagoty,
  242. Zblewo,
  243. Zgierz,
  244. Zielona Gora,
  245. Zielona Gora,
  246. Zielonka k/Warszawy,
  247. Zyrardow,
ALL GENDERS
0+
years
MULTIPLE SITES
Chronic Obstructive Pulmonary DiseaseTrial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).
NCT00523991
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Jasper, Alabama
  4. Palo Alto, California
  5. San Diego, California
  6. Lexington, Kentucky
  7. Baltimore, Maryland
  8. Bloomington, Minnesota
  9. Rochester, Minnesota
  10. Omaha, Nebraska
  11. Albuquerque, New Mexico
  12. Rochester, New York
  13. Charlotte, North Carolina
  14. Cincinnati, Ohio
  15. Pittsburgh, Pennsylvania
  16. Kingsport, Tennessee
  17. Clarksburg, West Virginia
  18. Gilly,
  19. Leuven,
  20. Menen,
  21. Yvoir,
  22. Vancouver, British Columbia
  23. Kingston, Ontario
  24. Toronto, Ontario
  25. Ste-Foy, Quebec
  26. Cvikov,
  27. Hradec Kralove,
  28. Karlovy Vary,
  29. Liberec,
  30. Neratovice,
  31. Pardubice,
  32. Praha 10,
  33. Praha 3,
  34. Praha 6,
  35. Strakonice,
  36. Tabor,
  37. Usti nad Labem,
  38. Berlin,
  39. Berlin,
  40. Gelnhausen,
  41. Rüdersdorf,
  42. Ulm,
  43. Athens,
  44. Athens,
  45. Thessaloniki,
  46. Enschede,
  47. Etten Leur,
  48. Spijkenisse,
  49. Zutphen,
  50. Amadora,
  51. Coimbra,
  52. Lisboa,
  53. Dnipropetrovsk,
  54. Kharkiv,
  55. Kharkov,
  56. Kharkov,
  57. Kiev,
  58. Kiev,
  59. Simferopol,
  60. Garston, Watford,
  61. Harrow,
  62. Warminster,
ALL GENDERS
40 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study of UK-369,003 on the Safety and Efficacy in Patients With COPD
Official Title  ICMJE A Multi-Centre, Multinational, Randomized, Double-Blind, Placebo Controlled, Proof Of Concept Trial To Assess The Effects Of A Subject-Optimized Dose Of UK-369,003 On Exercise Capacity In Subjects With Chronic Obstructive Pulmonary Disease
Brief Summary A randomised, controlled study investigating the effect of UK-369,003 on exercise tolerance in patients with COPD
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Pulmonary Disease, Chronic Obstructive
Intervention  ICMJE Drug: UK-369,003
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: September 11, 2005)		136
Original Enrollment  ICMJE Same as current
Study Completion Date  ICMJE December 2005
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • GOLD criteria 2 to 4
  • 10 pack year history of smoking

Exclusion Criteria:

  • Women of child bearing potential
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 35 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina,   Australia,   Germany,   India,   United Kingdom
Removed Location Countries Belgium
 
Administrative Information
NCT Number  ICMJE NCT00163098
Other Study ID Numbers  ICMJE A3711028
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date October 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP